BPC-157
Evidence: D/ERepair / Tissue Healing
Key facts
- Research areaRepair / Tissue Healing
- Research statusunclear
- Study records123 human
- Study-at-a-Glance1published summaries
- Last updated2026-07-26
Evidence Snapshot
What this grade covers
Three very small uncontrolled or retrospective human reports exist, but efficacy and general safety remain unestablished; most mechanism and repair evidence is preclinical.
Regulatory Context
No FDA-approved BPC-157 drug product was identified. FDA's 2026 staff evaluation proposed against adding BPC-157 free base and acetate to the 503A Bulks List, citing inadequate characterization, limited effectiveness evidence, and unresolved safety concerns. FDA convened the Pharmacy Compounding Advisory Committee on July 23, 2026; committee recommendations are advisory and do not constitute approval or final agency action. No final FDA action was identified as of the page's review date.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
An experimental synthetic pentadecapeptide available mainly through unapproved or compounded-product channels.
Why are researchers interested in it?
Animal, tissue, and cell research examines repair signaling, fibroblast behavior, blood-vessel biology, gastrointestinal models, and inflammatory pathways.
What is it being studied for?
- Tissue repair signaling (tendon and ligament)Animal / Cell / Preclinical Data
- Angiogenesis and blood-vessel biologyAnimal / Cell / Preclinical Data
- Gastrointestinal researchAnimal / Cell / Preclinical Data
- Inflammatory pathwaysAnimal / Cell / Preclinical Data
- Human safety and tolerability (very limited, uncontrolled)Human Studies & Clinical Data
What does the evidence look like?
Human evidence is extremely limited, uncontrolled, and insufficient to establish efficacy or general safety.
Biggest things to know
No approved BPC-157 drug exists, and product identity and quality remain uncertain. The July 23, 2026 FDA advisory-committee vote favoring possible compounding eligibility was nonbinding and did not create approval, an approved indication, or an approved dosing regimen.
What don't we know yet?
The three existing human reports are small, uncontrolled, and cannot establish whether BPC-157 is safe or effective, and almost all repair-related findings come from animal and cell studies that may not translate to humans. FDA's regulatory review is unresolved, and the July 2026 advisory-committee vote was nonbinding and did not approve any use.
Research status
Reviewed August 24, 2026
Research Takeaway
BPC-157 is a synthetic 15-amino-acid peptide discussed under inconsistent naming and product-characterization conventions; free base, acetate, and finished products should not be assumed equivalent.
See all 13 evidence claims →Quick Summary
BPC-157 is an experimental 15-amino-acid peptide promoted for repair and gastrointestinal uses. Published human evidence consists of two tiny uncontrolled pilots and one retrospective private-clinic report; most mechanistic support remains preclinical. FDA has identified significant product-characterization, impurity, aggregation, immunogenicity, and long-term safety uncertainties.
Mechanism & Research Overview
Preclinical work reports effects on tendon-cell migration and survival, cytoskeletal organization, FAK/paxillin signaling, nitric-oxide-related pathways, and angiogenic biology. These mechanisms are biologically interesting but do not demonstrate that a marketed BPC-157 product heals human injuries or treats gastrointestinal disease.
Mechanism pathway
Relationship-support labels describe the type and directness of the research available, not proof of safety or effectiveness. Indirectly supported, inferred and uncertain relationships are not equivalent to directly supported ones.
- CompoundBPC-157
- Inferred from related evidence (Inferred relationship, not directly demonstrated)Biological targetTarget Not Established
- Inferred from related evidence (Inferred relationship, not directly demonstrated)Signal / mechanism stepVEGFR2-associated angiogenic signalingPreclinical evidence associates BPC-157 with VEGFR2-linked angiogenic signaling.
- Inferred from related evidence (Inferred relationship, not directly demonstrated)Signal / mechanism stepNitric-oxide-system interactionPreclinical evidence associates BPC-157 with nitric-oxide-system signaling relevant to vascular/tissue-repair biology.
- Leads toPathwayNot yet assigned
Relationship details
- BPC-157 → Target not established — Inferred from related evidenceBPC-157 is associated with angiogenic and nitric-oxide-system signaling in preclinical models without a demonstrated direct-binding molecular target.
- VEGFR2-associated angiogenic signaling — Inferred from related evidence
- Nitric-oxide-system interaction — Inferred from related evidence
Research has not established a specific biological target for this relationship. Any downstream biology shown below is still reported, but is not tied to a confirmed target.
A specific pathway family has not yet been assigned for this relationship.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
BPC-157 is a synthetic 15-amino-acid peptide discussed under inconsistent naming and product-characterization conventions; free base, acetate, and finished products should not be assumed equivalent.
Sources: FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
A two-person intravenous pilot reported no short-term measured biomarker changes or self-reported adverse effects, but it cannot establish general, long-term, or route-independent safety.
Sources: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Supported
A 12-person uncontrolled interstitial-cystitis pilot reported self-assessed symptom improvement after a single procedure; the study is hypothesis-generating and does not establish efficacy.
Sources: Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
Supported
A retrospective knee-pain report found self-reported improvement in many contacted patients, but mixed interventions, lack of controls, nonstandardized outcomes, and variable follow-up prevent causal conclusions.
Sources: Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Supported
Rat tendon-explant and fibroblast experiments reported effects on outgrowth, migration, oxidative-stress survival, and FAK/paxillin signaling; these findings do not establish human tendon healing.
Supported
FDA identifies immunogenicity, aggregation, peptide-impurity, product-characterization, formulation, concentration, and storage concerns for compounded BPC-157.
Sources: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — BPC-157; FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
FDA’s 2026 evaluation found insufficient evidence of effectiveness for ulcerative colitis and proposed against adding BPC-157 free base and acetate to the 503A Bulks List.
Sources: FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
FDA convened the Pharmacy Compounding Advisory Committee on July 23, 2026 to discuss BPC-157-related bulk drug substances. The meeting and any advisory recommendation did not create FDA approval or final agency action.
Sources: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page; FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
Supported
The reviewed human evidence consists of a two-person intravenous pilot, a 12-person uncontrolled interstitial-cystitis report, and a retrospective knee-pain report; these studies do not establish efficacy for tendon, ligament, cartilage, muscle, gastrointestinal, or other commonly marketed indications.
Sources: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study; Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study; Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Supported
Reuters reported that on July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend possible inclusion of BPC-157 on the 503A Bulks List. The available secondary report did not distinguish between the free-base and acetate voting questions. The recommendation was advisory and nonbinding. It did not itself place BPC-157 on the 503A Bulks List, create FDA approval, establish safety or effectiveness, authorize a consumer product, or create an approved dosing regimen. No subsequent final FDA action was identified in the sources reviewed as of July 26, 2026.
Sources: Advisory Panel Vote on BPC-157
Supported
BPC-157 appears on the World Anti-Doping Agency's prohibited list under the non-approved-substances category; this sports rule is separate from FDA drug approval and compounding law.
Sources: The 2026 Prohibited List
Supported
Independent 2026 reviews of BPC-157's musculoskeletal evidence base and its translational-development barriers confirm that the broad preclinical literature has not translated into large randomized controlled human trials, and that much of the historical literature originates from a limited investigator network with unresolved formulation and replication barriers.
Sources: BPC-157 Musculoskeletal Evidence Review; BPC-157 Translational Development Barriers
Supported
A registered 2026 trial (NCT07437547) is investigating BPC-157 for acute grade-II hamstring injury. Registration or recruitment status does not establish safety or effectiveness and should not be reported as a positive result.
Sources: BPC-157 for Acute Hamstring Strain
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The published reports cannot establish efficacy, rare harms, long-term safety, or broad route equivalence.Safety Consideration
FDA found inconsistent naming and inadequate data for identity, aggregates, impurities, microbial quality, endotoxins, and other critical quality attributes.Safety Consideration
Peptide synthesis, formulation, concentration, storage, and route can change aggregation, impurities, pharmacological activity, and immune risk.Safety Consideration
Tendon-cell and animal-model effects should not be presented as proof of tendon, ligament, cartilage, muscle, or gastrointestinal repair in people.Safety Consideration
FDA staff proposed against 503A listing, but the July 23, 2026 advisory meeting had not occurred on the research review date.Safety Consideration
The 8-6 advisory-committee vote favoring possible 503A-list inclusion did not create FDA approval, establish safety or effectiveness, or create an approved dosing regimen. Final FDA action was not identified as of 2026-07-26.
Research Areas Being Studied
Research areas discussed on this page reflect the Repair / Tissue Healing category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
Show findings from 3 human studies
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025):
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (2024):
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021):
Study Tables by Evidence Type
12 study records · 1 with a Study-at-a-Glance summary
- Human Studies & Clinical Data 3
- Animal / Cell / Preclinical Data 1
- Regulatory Documents & Official Trial Registries 6
Human Studies & Clinical Data(3)
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
2021PMID 34324435
Study-at-a-Glance available
- Population / Model
- Sixteen contacted patients from a 17-patient retrospective chart review
- Dose / Duration / Finding
Most contacted patients reported pain improvement, but outcomes were nonstandardized and the intervention was mixed in four patients.
Safety note
No control group, inconsistent follow-up, heterogeneous diagnoses, self-reported pain, no standardized function or imaging outcomes, and a mixed-combination subgroup.
Key takeaway
A small retrospective chart review at one clinic found that 14 of 16 patients reported relief of knee pain after knee injections of BPC-157; the abstract describes no comparison group, and results were self-reported by phone.
Study at a Glance
Study at a Glance
Plain-language summary of: Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Evidence status
What was being studied?
Whether knee injections of the peptide BPC-157, alone or with thymosin beta-4 (TB4), were followed by less knee pain in patients seen for several different causes of knee pain.
Who participated?
17 patients in a 2019 to 2020 chart review at one clinic in Orlando, Florida; 16 were reached by phone.
How was the study done?
Retrospective, observational chart review with a follow-up phone survey, not a clinical trial. Patients had been injected 6 months to 1 year earlier (follow-up varied). They rated their pain before the injection, how long it helped and how much it helped. No measuring tools for function, stiffness or quality of life were used. Only the abstract was reviewed.
Key results
Of 16 patients, 12 received BPC-157 alone and 11 of those 12 (91.6%) reported significant improvement. 4 patients received BPC-157 plus TB4 and 75% reported significant improvement. Overall, 14 of 16 (87.5%) reported pain relief.
What does this mean?
Safety findings
Safety information was not available in the source reviewed.
Important limitations
- Very small sample (17 patients, 16 surveyed) from a single clinic.
- Retrospective chart review; the abstract describes no comparison group and no blinding.
- Outcomes were self-reported by phone, with no validated function or quality-of-life measures.
- Follow-up time varied between patients.
- Patients had different causes of knee pain, and some also received a second peptide, so effects cannot be attributed to BPC-157 alone.
- Only the abstract was reviewed; the full paper was not.
Sources
- Original study
- PubMed — PubMed
- Sources reviewed
- Abstract only — full text not reviewed.
This summary is a plain-language reading aid written by MitoCore. It does not replace the original study, which remains the authoritative source. Research information only, not medical advice.
Lee E, Padgett B. Altern Ther Health Med. 2021;27(4):8-13. PMID:34324435.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
2025PMID 40131143
- Population / Model
- Two adults with prior intravenous BPC-157 exposure
- Dose / Duration / Finding
No adverse effects or measured biomarker changes were reported after two consecutive-day infusions.
Safety note
Two previously exposed participants, no control group, short follow-up, and limited outcome assessment prevent general safety conclusions.
Lee E, Burgess K. Altern Ther Health Med. 2025;31(5):20-24. PMID:40131143.
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
2024PMID 39325560
- Population / Model
- Twelve women with moderate-to-severe interstitial cystitis who had not responded to pentosan polysulfate
- Dose / Duration / Finding
Participants reported substantial symptom improvement on a Global Response Assessment after one procedure.
Safety note
No control group, blinding, standardized comparator, independent replication, or robust adverse-event ascertainment.
Lee E, et al. Altern Ther Health Med. 2024;30(10):12-17. PMID:39325560.
Animal / Cell / Preclinical Data(1)
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
2011PMID 21030672 · DOI 10.1152/japplphysiol.00945.2010
- Population / Model
- Rat tendon explants and cultured rat tendon fibroblasts
- Dose / Duration / Finding
BPC-157 increased explant outgrowth, cell survival under oxidative stress, migration, spreading, and FAK/paxillin phosphorylation in the experimental systems.
Safety note
Cell and tissue findings do not establish human tendon healing, injury recovery, or clinical safety.
Chang CH, et al. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010.
Regulatory Documents & Official Trial Registries(6)
Advisory Panel Vote on BPC-157
2026- Population / Model
- Dose / Duration / Finding
On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend possible 503A-list inclusion for BPC-157. The vote was advisory and nonbinding and did not create FDA approval, establish safety or effectiveness, or authorize a consumer product.
Show full finding
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — BPC-157
2026- Population / Model
- FDA compounding safety review
- Dose / Duration / Finding
FDA identifies route-dependent immunogenicity, peptide-impurity, API-characterization, and insufficient safety-information concerns.
Safety note
FDA states that it lacks sufficient information to know whether compounded BPC-157 would cause harm when administered to humans by the proposed routes.
FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Reviewed 2026-07-19.
FDA evaluation of BPC-157-related bulk drug substances for the 503A Bulks List
2026- Population / Model
- FDA Pharmacy Compounding Advisory Committee briefing
- Dose / Duration / Finding
FDA found BPC-157 insufficiently characterized, found insufficient evidence of effectiveness for ulcerative colitis, and proposed that free base and acetate not be added to the 503A Bulks List.
Safety note
FDA highlighted aggregation, peptide impurities, route- and formulation-specific risk, inadequate long-term clinical safety, and uncertain adverse-event causality. The proposal preceded the July 23, 2026 committee meeting and was not a final committee outcome on the review date.
FDA Briefing Document: BPC-157-related bulk drug substances. May 11, 2026.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page
2026- Population / Model
- FDA advisory-committee calendar
- Dose / Duration / Finding
The meeting was scheduled after the MitoCore research review date, so no final committee vote or post-meeting FDA action was available for this pack.
Safety note
Regulatory wording must be updated after the meeting and any subsequent FDA action.
FDA advisory committee calendar. July 23-24, 2026 PCAC meeting.
The 2026 Prohibited List
2026- Population / Model
- Anti-doping regulatory list
- Dose / Duration / Finding
BPC-157 is prohibited at all times under the 2026 WADA list.
Safety note
Anti-doping status is not a clinical safety or efficacy determination.
BPC-157 for Acute Hamstring Strain
NCT07437547
- Population / Model
- Dose / Duration / Finding
A registered 2026 trial is designed to investigate BPC-157 for acute grade-II hamstring injury. Registration or recruitment status does not establish safety or effectiveness and should not be reported as a positive result.
Review Articles / Secondary Sources(2)
BPC-157 Musculoskeletal Evidence Review
PMID 40789979
- Population / Model
- Dose / Duration / Finding
A 2026 review of BPC-157 musculoskeletal evidence found that human clinical evidence remains limited to small, uncontrolled, or retrospective reports and does not establish that BPC-157 heals tendons, ligaments, muscle, or cartilage in humans.
BPC-157 Translational Development Barriers
PMID 42198317
- Population / Model
- Dose / Duration / Finding
A 2026 review of BPC-157 translational development barriers found that much of the historical preclinical literature originates from a limited investigator network, and that formulation, replication, and translation to human trials remain significant unresolved barriers.
Show full finding
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
BPC-157 remains experimental. Small uncontrolled human reports and preclinical studies do not establish a safe or effective treatment for injury repair, pain, gastrointestinal disease, or recovery.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-26.
Follow research updates for BPC-157
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.